DIASORIN LAUNCHES THE NEW N-TACT PTH GEN II ON ITS LIAISON PLATFORM WORLDWIDE

February 18, 2014 - Saluggia (VC) - DiaSorin (FTSE Mid Cap:DIA) is pleased to announce the launch of a new product in its portfolio, the LIAISON N-TACT PTH Gen II assay, for the quantitative determination of intact human parathyroid hormone (PTH) in human serum and plasma.

The LIAISON N-TACT PTH Gen II assay is a redevelopment of our existing N-TACT PTH assays and employs specific polyclonal antibodies to assist in diagnosis of disorders of calcium metabolism. This assay is an addition to the current DiaSorin LIAISON Bone and Mineral menu made of both specialty and main stream tests such as the 25-OH Vitamin D TOTAL Assay, 1-84 PTH, BAP OSTASE and Osteocalcin.

Francesco Colotta, Senior Corporate V.P and Chief Medical Officer in DiaSorin, explained:” The main function of PTH is to regulate serum calcium levels within the body; when serum calcium levels are high, the parathyroid glands, located at the back of the thyroid gland, are stimulated to decrease the production of PTH which lowers serum calcium levels; when serum calcium levels are low, PTH secretion is increased. In cases when this process is not functioning correctly, the consequence is a condition called Hyperparathyroidism, which is caused by the over secretion of PTH by the parathyroid glands”.

Primary hyperparathyroidism is characterized by abnormal over secretion of parathyroid hormone typically as a result of a parathyroid tumor. According to recent studies, its prevalence in the general population is estimated less than 1%. Whereas secondary hyperparathyroidism is an appropriately high PTH level, which is caused by disorders of calcium and phosphate metabolism. Secondary hyperparathyroidism is commonly found in patients suffering from chronic kidney disease which is a growing health issue with an estimated prevalence exceeding 10% worldwide.

According to EDMA analysis and an internal estimation, the potential Market in Europe and USA for the LIAISON N-TACT PTH Gen II assay is around €43 million.
Carlo Rosa, CEO of DiaSorin Group, commented: "With this new assay we demonstrate once again our commitment in providing tests that guarantee accuracy of results. Furthermore the new launch in the Bone and Mineral clinical area clearly shows our aim to strengthen our positioning in this segment worldwide and in particular in the United States where we are already known for our Endocrinology and Bone and Mineral products and where we plan to be a key player."

About DiaSorin
Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

Riccardo Fava  
External Relations Director - Head of IR and Media  
Tel: +39.0161.487988  
riccardo.fava@diasorin.it

Margherita Sacerdoti  
Investor Relations Specialist  
Tel: +39.0161.487456  
margherita.sacerdoti@diasorin.it